MedX Health Corp. (TSX-V: MDX) has applied to the TSX Venture Exchange for a 30-day extension to April 15, 2026, to complete additional closings of its non-brokered private placement of Series IV Convertible Loan Notes.

The company completed an initial closing on February 27, 2026, raising $2.7 million in Series IV Notes. The extension would allow MedX to raise up to an additional $2.3 million through further closings.

The Series IV Notes carry a 6% annual interest rate with quarterly payments and mature on December 31, 2028. Note holders may convert their investment into units at $0.10 per unit before the maturity date. Each unit consists of one common share and half of a share purchase warrant, with each whole warrant exercisable at $0.125 until maturity.

Qualified agents will receive a 6% cash commission on gross proceeds from subscribers they introduce, plus agent's warrants equal to 6% of those subscriptions. The agent's warrants are non-transferable and exercisable at $0.10 for units containing one common share and half of an agent's share purchase warrant.

MedX stated that certain company insiders are expected to participate in the placement, subject to regulatory compliance. The company plans to rely on exemptions from formal valuation and minority shareholder approval requirements under Multilateral Instrument 61-101.

Proceeds will fund redemption of Series I Notes not converted to Series IV Notes, continued development of the company's SIAscopy technology on the DermSecure telemedicine platform, expansion into occupational health markets, and general corporate purposes.

MedX Health develops medical technology for non-invasive skin screening and teledermatology using proprietary imaging technology.